COVID-19 Pneumonia
Conditions
Keywords
Comorbidities, Outcomes, Covid-19
Brief summary
COVID-19, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is a multisystem disease which primarily involves the respiratory tract. The first case of COVID-19 was identified in late 2019 in the province of Wuhan, China which was followed by the rapid spread of the disease globally, becoming a present-day pandemic. Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore.
Detailed description
Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore. Material & Methods: Study design: Retrospective study. Study Settings: Study was conducted in Fatima Memorial Hospital, Lahore. Study Duration: Study was conducted on Covid-19 patients who were admitted from March 2021 to August 2021.
Interventions
COMBINATION_PRODUCTPatients with COVID-19 Pneumonia
Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
Sponsors
FMH College of Medicine and Dentistry
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Critically sick patients with COVID-19 Pneumonia * All admitted ICU patients with a diagnosis of COVID-19 pneumonia * Patients having positive reverse transcriptase PCR for COVID-19 * Patients with High-resolution computed tomography (HRCT) chest findings suggestive of COVID-related lung injury * All patients above 16 years of age with both genders( males and females)
Exclusion criteria
* All patients with PCR negative with mild symptoms * Patients with No signs of COVID-19 pneumonia on HRCT chest
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 6 months | The primary endpoint of the study will be to assess the ICU mortality (in percentages% and Numbers) of critically sick patients with COVID-19 pneumonia admitted to the intensive care unit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comorbidities | 6 months | we will assess various comorbidities in critically sick patients with COVID-19 pneumonia admitted to the intensive care unit |
Countries
Pakistan
Outcome results
None listed